This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Neurology, Other  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The article on antihypertensive medication use and incident Alzheimer disease (AD) in the Cache County Study¹ discloses that the use of a potassium-retaining diuretic at baseline, but not the use of a thiazidelike or a loop diuretic, was associated with reduced incidence of AD over the following years in subjects aged 65 years or older.

The set of potassium-retaining diuretics comprises 2 subsets. The epithelial sodium channel blockers amiloride and triamterene cause renal retention of potassium in all circumstances, whereas aldosterone antagonists (eg, spironolactone, eplerenone) act as natriuretics, diuretics, and antikaliuretics only if plasma aldosterone is raised, as happens, inter alia, when a sodium-restricted diet is followed or a thiazidelike or a loop diuretic is used.² Khachaturian et al¹ speculate on the mechanism of the negative relationship between the use of potassium-retaining diuretics and the risk of AD they found by considering several possibilities stemming from renal potassium retention. I . . . [Full Text of this Article]

AUTHOR INFORMATION

Ariel J. Reyes, MD

RELATED ARTICLE

Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Ara S. Khachaturian, Peter P. Zandi, Constantine G. Lyketsos, Kathleen M. Hayden, Ingmar Skoog, Maria C. Norton, JoAnn T. Tschanz, Lawrence S. Mayer, Kathleen A. Welsh-Bohmer, John C. S. Breitner, and for the Cache County Study Group
Arch Neurol. 2006;63(5):686-692.
ABSTRACT | FULL TEXT